Does ALIROCUMAB Cause Neoplasm malignant? 57 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 57 reports of Neoplasm malignant have been filed in association with ALIROCUMAB (Praluent). This represents 0.3% of all adverse event reports for ALIROCUMAB.
57
Reports of Neoplasm malignant with ALIROCUMAB
0.3%
of all ALIROCUMAB reports
8
Deaths
10
Hospitalizations
How Dangerous Is Neoplasm malignant From ALIROCUMAB?
Of the 57 reports, 8 (14.0%) resulted in death, 10 (17.5%) required hospitalization, and 3 (5.3%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ALIROCUMAB. However, 57 reports have been filed with the FAERS database.
What Other Side Effects Does ALIROCUMAB Cause?
Myalgia (1,571)
Product dose omission (1,354)
Injection site pain (1,220)
Muscle spasms (1,113)
Arthralgia (993)
Fatigue (922)
Pain (892)
Pain in extremity (888)
Product dose omission issue (864)
Injection site bruising (821)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which ALIROCUMAB Alternatives Have Lower Neoplasm malignant Risk?
ALIROCUMAB vs ALISKIREN
ALIROCUMAB vs ALISKIREN HEMIFUMARATE
ALIROCUMAB vs ALISKIREN\HYDROCHLOROTHIAZIDE
ALIROCUMAB vs ALIZAPRIDE
ALIROCUMAB vs ALLANTOIN